The international journal of therapeutic innovation (IJTI) accepts research, reviews, and case studies that are of primary interest to medical, medical oncology and immunologists, pharmaceuticals, public health workers, and infectious disease clinicians. The articles should present comprehensive, critical summaries of current knowledge in the field, in other words, authoritative narrative research/review articles. The content of the article should not be limited to a discussion of the author's work. Sufficient historical or other background material may be included for those readers who are not current with the latest advances in the particular field. If the material covered is controversial, the author should attempt to provide balanced coverage.

International journal of therapeutic innovation (www.ijtinnovation.com) covers research studies/reviews related to Medical and pharmaceuticals including all of the allied subjects. Articles with timely interest and newer research concepts are given more preference.

The international journal of therapeutic innovation (www.ijtinnovation.com) is a Dingle-blind, peer-reviewed open access scientific journal. We are fulfilling all guidelines of Scopus, Index Copernicus, and UGC so that we can get the indexing. This will helps our authors to prove the high impact factor for their manuscript. Journal offers authors fast review and decision times; a continuous-publication format; and global distribution for their research work. All manuscripts are precisely copyedited and typeset to ensure quality.

The journal publishes scientific articles in all areas of Medical, and pharmaceutical including all the basic science subjects. We welcome both review and research papers and place great value on applying high-quality standards.

The international journal of therapeutic innovation (www.ijtinnovation.com) endeavors to gain and maintain its reputation as the most prominent scientific journal internationally. We are willing to become a major internationally recognized journal. The journal is receptive to high-quality manuscripts on different scientific topics.

The journal operates a double-blind peer-review system, where both the reviewer and the author are anonymous to each other. All articles published are made freely and permanently accessible online immediately upon publication, without subscription charges or registration process. Further information about open access can be found at www.ijtinnovation.com. As authors of articles published in the international journal of therapeutic innovation (www.ijtinnovation.com) you are the copyright holders of your article and have granted to any third party, in advance, and in perpetuity, the right to use reproduce or disseminate your article, according to the journal of medical pharmaceutical and allied sciences copyright and license agreement.

For those authors who are government employees or are prevented from being copyright holders for similar reasons, the international journal of therapeutic innovation (www.ijtinnovation.com) can accommodate non-standard copyright lines. Please contact info@ijtinnovation.com if further information is needed.